和铂医药宣布新一代CTLA-4抗体授权交易；前沿生物与葛兰素史克签署授权许可协议 | 医药早参

Group 1 - Heptares Pharmaceuticals has entered into a licensing and equity cooperation agreement with Solstice Oncology for HBM4003, granting exclusive rights for development and commercialization outside Greater China, with potential upfront payments exceeding $105 million [1] - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, one of which is in the IND stage, marking a significant breakthrough in its international strategy [2] - CStone Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency for a new indication of Sugli monoclonal antibody for treating adult patients with advanced non-small cell lung cancer, highlighting its progress in global operations [3] Group 2 - Novo Nordisk's stock has dropped significantly following disappointing clinical data for CagriSema, which showed only a 23% weight loss effect, failing to meet the primary endpoint of the trial [4] - Tongce Medical's chairman and executives plan to increase their shareholding in the company, with a commitment to buy between 6 million and 12 million yuan worth of shares, amid pressures from weak consumer demand and dental implant procurement [5]